---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-112235"
form_type: "8-K"
ticker: "CVRX"
cik: "0001235912"
company_name: "CVRx, Inc."
filed_at: "2024-10-29T23:59:59+00:00"
generated_at: "2026-05-30T08:53:55.653276+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CVRx Q3 revenue rose 27% to $13.4M; net loss widened to $13.1M

## Summary
- US HF revenue $12.2M (+30% YoY) driven by territory expansion and new accounts.
- Net loss of $13.1M ($0.57/share) vs $9.0M ($0.43/share) a year ago; SG&A expenses up 38%.
- Active implanting centers reached 208, up 31% YoY; cash $100.2M after drawing $20M loan tranche.
- CMS reassigned Barostim to MS-DRG 276, raising inpatient payment to ~$43,000 from $17-23K.
- FY2024 revenue guidance narrowed to $50.5-51.5M (from $50-53M); operating expense guidance raised to ~$100M.

## SEC filing metadata
- accession: 0001104659-24-112235
- form_type: 8-K
- ticker: CVRX
- cik: 0001235912
- company_name: CVRx, Inc.
- filed_at: 2024-10-29T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1235912/000110465924112235/0001104659-24-112235-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1235912/000110465924112235/tm2427008d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-112235
- JSON: https://secwatch.observer/filing/0001104659-24-112235.json
- Plain text: https://secwatch.observer/filing/0001104659-24-112235.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.